Project Grant R43DK130751
Award Date 9/20/21
Completion Date 8/31/23
Dollars Obligated $808K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- This National Science Foundation Project Grant of $100,000 supports the development of a self-assembling, protein-based contrast agent targeted to collagen type 1 for non-alcoholic fatty liver disease diagnosis and monitoring. Funded under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the award to New York University will support research and innovation leading to a breakthrough biomedical imaging technology. Specifically, the university will develop a recombinant...
- Federal Grant Award Summary New York University School of Medicine received an $830,401 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 15, 2025, with completion targeted for July 31, 2030. The award supports the development and validation of fat and iron-corrected quantitative MRI T1 mapping technology for non-invasive evaluation...
- Summary of AI-LIVER Federal Project Grant Award The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded Icahn School of Medicine at Mount Sinai a $3.39 million Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) for the three-year period from September 1, 2025, through August 31, 2028. The AI-LIVER project delivers two primary products: (1) establishment of an international cohort of...
- Federal Project Grant Award Summary Mayo Clinic received a $202,176 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to develop innovative diagnostic and prognostic tools for steatotic liver diseases. The award, effective September 15, 2025, through August 31, 2030, supports research applying machine learning and multi-omics data integration to distinguish between alcohol-associated liver disease (ALD),...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases awarded a $789,828 Project Grant to the University of Pennsylvania (awarded June 1, 2026, with completion targeted for February 28, 2030) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant funds the development of theoretical and computational models validated through experimental research to explain disease progression in metabolic...
- Summary The Children's Hospital of Philadelphia received $837,620 in project grant funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for the project "Multimodal Imaging Biomarkers of Liver Disease Progression in ARPKD." The award, effective July 1, 2026, through April 30, 2031, funds the development and validation of quantitative, non-invasive imaging...
- Federal Grant Award Summary Mayo Clinic received a $149,190 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 30, 2026, with completion targeted for March 30, 2029. The award funds fundamental biomedical research investigating metabolism-mediated epigenetic regulation of hepatic stellate cell activation during liver fibrosis progression....
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Indiana University Indianapolis a Project Grant of $480,697 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct basic biomedical research on hepatic fibrosis mechanisms. The five-year award, effective March 1, 2026 through February 28, 2031, supports research investigating Sestrin 3 (SESN3) as a therapeutic target for metabolic...
- Federal Grant Award Summary Vanderbilt University Medical Center received $874,741 in federal funding from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for a Project Grant awarded June 1, 2026, with completion targeted for February 28, 2030. The award supports research investigating the transcriptional mechanisms of fibrosis in metabolic dysfunction-associated steatohepatitis...
- Federal Grant Award Summary The Medical University of South Carolina received a $1.98 million Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award, effective September 1, 2025, through August 31, 2029, supports research and development of advanced fibrosis detection methodologies and a predictive diagnostic model for Metabolic Dysfunction-Associated...